News & Press

Oct 15, 2026
Portfolio Company News arrow up right

OMass Therapeutics Announces $310 Million Series C Financing to Advance Portfolio of Small Molecule Therapeutics in Endocrinology and Immunology

Financing co-led by new investors Bain Capital Life Sciences, Forbion and Novo Holdings, with strong participation from additional new...
Aug 17, 2026
Portfolio Company News arrow up right

Juvena Therapeutics Appoints Julie Anne Smith as Chief Executive Officer

Accomplished rare disease and neuromuscular biotech executive joins as company advances JUV-161 through Phase 2 clinical development and executes global Eli Lilly collaboration.
Jul 24, 2026
Portfolio Company News arrow up right

Draig Therapeutics Closes Oversubscribed $65 Million Series B to Accelerate Development of Highly Specific AMPA and GABAA Receptor Modulators in Neuropsychiatric Disorders

Financing led by new investor, Deep Track Capital with participation from Janus Henderson Investors and Marshall Wace among other investors Proceeds will support accelerated clinical advancement of company’s pipeline, including lead program DT-101, an AMPA receptor potentiator designed to address significant unmet need in major depressive disorder
Jun 10, 2026
Portfolio Company News arrow up right

FesariusTherapeutics Closes Oversubscribed $20M Series A, Led by Jefferson Life Sciences, and Backed by NY Ventures, and the American Society of Plastic Surgeons

DermiSphere™, the first of its kind hydrogel Dermal Regeneration Template, attracts world-class financial and strategic investors as clinical momentum accelerates
Jan 13, 2026
Portfolio Company News arrow up right

Juvena Therapeutics Raises $33.5M Series B Led by Bison Ventures to Advance Regenerative Biologics Pipeline

Juvena Therapeutics, a clinical-stage biotechnology company whose AI-enabled regenerative biologics are designed to restore tissue function, today announced its $33.5 million Series B.
Oct 08, 2025
JLS Press Release arrow up right

Jefferson River Capital Launches New Life Sciences Investment Fund, Jefferson Life Sciences

Names Veteran Biotech Entrepreneur and Executive, Laura Lande-Diner, as Managing PartnerAnnounces investments in Character Biosciences and Juvena Therapeutics
Jul 23, 2025
JLS Press Release arrow up right

Character Biosciences Raises $93 Million Series B to Advance Precision Medicine for Progressive Eye Diseases

Funding will enable lead candidates CTX114 and CTX203 for AMD to enter clinical trials in the next year